In this video, Yasha S. Modi, MD, discusses the 2-year results of the GATHER2 trial, which showed that avacincaptad pegol had a positive effect on geographic atrophy reduction.
The data, presented at the American Academy of Ophthalmology meeting, indicated that patients treated with avacincaptad pegol every other month did as well with progression rate as patients treated every month, Modi said.
“This was not a prespecified endpoint, and I think we need to understand a little bit more about that data,” Modi, associate professor, department of ophthalmology at NYU Grossman School of